^
BIOMARKER:
HER-2 exon 20 insertion
i
Other names: ERBB2, CD340, HER-2, HER2, NEU, NGL, V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2
Entrez ID:
Related biomarkers:
›
HER-2 exon 20 insertion
|
Solid Tumor
|
HER-2 exon 20 insertion
|
Solid Tumor
|
BDTX-189 Sensitive: B - Late Trials
|
BDTX-189 Sensitive: B - Late Trials
|
HER-2 exon 20 insertion
|
LUAD
|
HER-2 exon 20 insertion
|
LUAD
|
ado-trastuzumab emtansine Sensitive: C3 – Early Trials
|
ado-trastuzumab emtansine Sensitive: C3 – Early Trials
|
HER-2 exon 20 insertion
|
NSCLC
|
HER-2 exon 20 insertion
|
NSCLC
|
dacomitinib Sensitive: C3 – Early Trials
|
dacomitinib Sensitive: C3 – Early Trials
|
HER-2 exon 20 insertion
|
NSCLC
|
HER-2 exon 20 insertion
|
NSCLC
|
rivoceranib + pyrotinib Sensitive: C3 – Early Trials
|
rivoceranib + pyrotinib Sensitive: C3 – Early Trials
|
HER-2 exon 20 insertion
|
NSCLC
|
HER-2 exon 20 insertion
|
NSCLC
|
KN046 Sensitive: C3 – Early Trials
|
KN046 Sensitive: C3 – Early Trials
|
HER-2 exon 20 insertion
|
LUAD
|
HER-2 exon 20 insertion
|
LUAD
|
afatinib Sensitive: C4 – Case Studies
|
afatinib Sensitive: C4 – Case Studies
|
HER-2 exon 20 insertion
|
HER2 Positive Breast Cancer
|
HER-2 exon 20 insertion
|
HER2 Positive Breast Cancer
|
neratinib + ado-trastuzumab emtansine Sensitive: D – Preclinical
|
neratinib + ado-trastuzumab emtansine Sensitive: D – Preclinical
|
HER-2 exon 20 insertion
|
HER2 Positive Breast Cancer
|
HER-2 exon 20 insertion
|
HER2 Positive Breast Cancer
|
neratinib + fam-trastuzumab deruxtecan-nxki Sensitive: D – Preclinical
|
neratinib + fam-trastuzumab deruxtecan-nxki Sensitive: D – Preclinical
|
HER-2 exon 20 insertion
|
LUAD
|
HER-2 exon 20 insertion
|
LUAD
|
HM 78136B Sensitive: D – Preclinical
|
HM 78136B Sensitive: D – Preclinical
|
